These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 18395356)

  • 21. Phase I-II trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer.
    Rödel C; Arnold D; Hipp M; Liersch T; Dellas K; Iesalnieks I; Hermann RM; Lordick F; Hinke A; Hohenberger W; Sauer R
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1081-6. PubMed ID: 17881150
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preoperative radiotherapy of advanced rectal cancer with capecitabine and oxaliplatin with or without cetuximab: A pooled analysis of three prospective phase I-II trials.
    Weiss C; Arnold D; Dellas K; Liersch T; Hipp M; Fietkau R; Sauer R; Hinke A; Rödel C
    Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):472-8. PubMed ID: 20133081
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase II study of cetuximab, capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer.
    Velenik V; Ocvirk J; Oblak I; Anderluh F
    Eur J Surg Oncol; 2010 Mar; 36(3):244-50. PubMed ID: 20042310
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term follow-up of preoperative pelvic radiation therapy and concomitant boost irradiation in locally advanced rectal cancer patients: a multi-institutional phase II study (KROG 04-01).
    Lee JH; Kim DY; Nam TK; Yoon SC; Lee DS; Park JW; Oh JH; Chang HJ; Yoon MS; Jeong JU; Jang HS
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):955-61. PubMed ID: 22537540
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neoadjuvant treatment with single-agent cetuximab followed by 5-FU, cetuximab, and pelvic radiotherapy: a phase II study in locally advanced rectal cancer.
    Bertolini F; Chiara S; Bengala C; Antognoni P; Dealis C; Zironi S; Malavasi N; Scolaro T; Depenni R; Jovic G; Sonaglio C; Rossi A; Luppi G; Conte PF
    Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):466-72. PubMed ID: 19004567
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I study of 5-fluorouracil and leucovorin by continuous infusion chronotherapy and pelvic radiotherapy in patients with locally advanced or recurrent rectal cancer.
    Parulekar W; de Marsh RW; Wong R; Mendenhall W; Davey P; Zlotecki R; Berry S; Rout WR; Bjarnason GA
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1487-95. PubMed ID: 15050328
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II study of capecitabine (Xeloda) and concomitant boost radiotherapy in patients with locally advanced rectal cancer.
    Krishnan S; Janjan NA; Skibber JM; Rodriguez-Bigas MA; Wolff RA; Das P; Delclos ME; Chang GJ; Hoff PM; Eng C; Brown TD; Crane CH; Feig BW; Morris J; Vadhan-Raj S; Hamilton SR; Lin EH
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):762-71. PubMed ID: 17011451
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preoperative concurrent radiotherapy with capecitabine before total mesorectal excision in locally advanced rectal cancer.
    Kim JC; Kim TW; Kim JH; Yu CS; Kim HC; Chang HM; Ryu MH; Park JH; Ahn SD; Lee SW; Shin SS; Kim JS; Choi EK
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):346-53. PubMed ID: 15913913
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-dose radiotherapy (60 Gy) with oral UFT/folinic acid and escalating doses of oxaliplatin in patients with non-resectable locally advanced rectal cancer (LARC): a phase I trial.
    Vestermark LW; Jensen HA; Pfeiffer P
    Acta Oncol; 2012 Mar; 51(3):311-7. PubMed ID: 22248062
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chemoradiotherapy followed by surgery in rectal cancer: improved local control using a moderately high pelvic radiation dose.
    Lee SH; Lee KC; Choi JH; Oh JH; Baek JH; Park SH; Shin DB
    Jpn J Clin Oncol; 2008 Feb; 38(2):112-21. PubMed ID: 18263881
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Phase I study of postoperative concurrent chemoradiation with capecitabine as adjuvant treatment for stage II/III operable rectal cancer].
    Jin J; Li YX; Liu YP; Wang WH; Li T; Li N; Song YW
    Zhonghua Zhong Liu Za Zhi; 2006 May; 28(5):393-6. PubMed ID: 17045010
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II study of weekly intravenous oxaliplatin combined with oral daily capecitabine and radiotherapy with biologic correlates in neoadjuvant treatment of rectal adenocarcinoma.
    Fakih MG; Bullarddunn K; Yang GY; Pendyala L; Toth K; Andrews C; Rustum YM; Ross ME; Levea C; Puthillath A; Park YM; Rajput A
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):650-7. PubMed ID: 18565686
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ten years of preoperative chemoradiation for extraperitoneal T3 rectal cancer: acute toxicity, tumor response, and sphincter preservation in three consecutive studies.
    Valentini V; Coco C; Cellini N; Picciocchi A; Fares MC; Rosetto ME; Mantini G; Morganti AG; Barbaro B; Cogliandolo S; Nuzzo G; Tedesco M; Ambesi-Impiombato F; Cosimelli M; Rotman M
    Int J Radiat Oncol Biol Phys; 2001 Oct; 51(2):371-83. PubMed ID: 11567811
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dose-effect relationship in chemoradiotherapy for locally advanced rectal cancer: a randomized trial comparing two radiation doses.
    Jakobsen A; Ploen J; Vuong T; Appelt A; Lindebjerg J; Rafaelsen SR
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):949-54. PubMed ID: 22592048
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preoperative chemoradiation for extraperitoneal T3 rectal cancer: acute toxicity, tumor response, and sphincter preservation.
    Valentini V; Coco C; Cellini N; Picciocchi A; Genovesi D; Mantini G; Barbaro B; Cogliandolo S; Mattana C; Ambesi-Impiombato F; Tedesco M; Cosimelli M
    Int J Radiat Oncol Biol Phys; 1998 Mar; 40(5):1067-75. PubMed ID: 9539561
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Investigation of the comparative toxicity of 5-FU bolus versus 5-FU continuous infusion circadian chemotherapy with concurrent radiation therapy in locally advanced rectal cancer.
    Thrall MM; Wood P; King V; Rivera W; Hrushesky W
    Int J Radiat Oncol Biol Phys; 2000 Mar; 46(4):873-81. PubMed ID: 10705008
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Concurrent Chemoradiation with Concomitant Boost in Locally Advanced Rectal Cancer: A Phase II Study.
    Picardi V; Deodato F; Guido A; Giaccherini L; Macchia G; Gambacorta MA; Arcelli A; Farioli A; Cellini F; Cuicchi D; DI Fabio F; Poggioli G; Ardizzoni A; Frezza G; Cilla S; Caravatta L; Valentini V; Fuccio L; Morganti AG
    Anticancer Res; 2016 Aug; 36(8):4081-7. PubMed ID: 27466517
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prospective trial of preoperative concomitant boost radiotherapy with continuous infusion 5-fluorouracil for locally advanced rectal cancer.
    Janjan NA; Crane CN; Feig BW; Cleary K; Dubrow R; Curley SA; Ellis LM; Vauthey J; Lenzi R; Lynch P; Wolff R; Brown T; Pazdur R; Abbruzzese J; Hoff PM; Allen P; Brown B; Skibber J
    Int J Radiat Oncol Biol Phys; 2000 Jun; 47(3):713-8. PubMed ID: 10837955
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined modality therapy of rectal cancer: decreased acute toxicity with the preoperative approach.
    Minsky BD; Cohen AM; Kemeny N; Enker WE; Kelsen DP; Reichman B; Saltz L; Sigurdson ER; Frankel J
    J Clin Oncol; 1992 Aug; 10(8):1218-24. PubMed ID: 1634912
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Phase II study of preoperative radiotherapy and concomitant weekly irinotecan in combination with protracted venous infusion 5-fluorouracil, for resectable locally advanced rectal cancer.
    Navarro M; Dotor E; Rivera F; Sánchez-Rovira P; Vega-Villegas ME; Cervantes A; García JL; Gallén M; Aranda E
    Int J Radiat Oncol Biol Phys; 2006 Sep; 66(1):201-5. PubMed ID: 16814947
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.